Citations 2
Endoscopic Management of Variceal Band Ligation Leading to Acute Esophageal Obstruction
Quinteros, Mischelle Lopez, Zayat, Marisa S., Lukens, Frank J., Wagh, Mihir S., Hashash, Jana, Woodward, Timothy A., Lopez Quinteros, Mischelle, Petrov, Jessica C , Zayat, Marisa-Nicole , Lukens, F, Osagiede, Osayande
ACG Case Reports Journal | April 28, 2026 | Volume: 13 | Issue: 5 | Pages: No page available
ABSTRACT Complete esophageal obstruction is a rare but serious complication of endoscopic variceal band ligation (EVBL). We present the case of a 75-year-old man with cirrhosis and esophageal varices who developed acute esophageal obstruction following EVBL, which was successfully managed with a combination of endoscopic scissors to cut the band and through-the-scope balloon dilation, restoring luminal patency and recanalization of the esophagus. This case highlights the importance of prevention, early recognition, and timely management of this rare but important complication of EVBL. Key management options addressed include preventive, conservative, and interventional strategies to improve patient outcomes.
SGLT ‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes
Kim, Do Han , Ko, Donghyun , Chen, Vincent L., Porres, J.A., Alatorre, Carlos, Nieto, Luis M., Argueta, Pedro Palacios , Lukens, F, Kim, Donghee, Karagozian, Raffi, Bansal, Meena B. , Wijarnpreecha, Karn, Kim, Donghee , Nieto, Luis M. , Kim, Do Han , Chen, V L , Palacios Argueta, Pedro , Lukens, Frank J., Kim, Donghee , Ko, Donghyun , Alatorre, Carlos Elizondo, Kröner, Paul T. , Wijarnpreecha, Karn
Liver International | December 27, 2025 | Volume: 46 | Issue: 2 | Pages: No page available
ABSTRACT Introduction Metabolic dysfunction‐associated steatotic liver disease (MASLD) and steatohepatitis (MASH) represent a spectrum of liver conditions that can gradually progress to cirrhosis. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have shown benefits in reducing hepatic steatosis and liver‐related events in MASLD. This study aims to assess whether SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality and disease‐specific outcomes in patients with MASH cirrhosis and type 2 diabetes (T2D). Methods A retrospective cohort study was performed using TriNetX. Patients with T2D and MASH cirrhosis on SGLT‐2 inhibitors were matched 1:1 with other glucose‐lowering drugs (oGLDs) based on demographics, comorbidities and medications. Primary outcomes included all‐cause mortality, hepatic decompensation and major adverse liver outcomes (MALO). Cox‐proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence interval (CI). Results A total of 51 427 patients with MASH cirrhosis and T2D were identified, of which 6833 (13.28%) were on SGLT‐2 inhibitors. Patients on SGLT‐2 inhibitors ( n = 6449, mean age 63.7 years, 52.9% female) were matched with 6449 individuals (mean age 63.9 years, 53.5% female) on oGLDs. The SGLT‐2 inhibitors cohort had statistically significantly lower risk of all‐cause mortality (HR: 0.58, 95% CI: 0.53–0.63), hepatic decompensation (HR: 0.85, 95% CI: 0.81–0.90) and MALO (HR: 0.88, 95% CI: 0.83–0.93). Conclusion SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality in patients with MASH cirrhosis and T2DM, which may be partly attributable to a lower risk of hepatic decompensation and subsequent events. Further studies are warranted as SGLT‐2 inhibitors may serve as an adjunctive therapy for patients with MASH cirrhosis.